RxDoctor Payments Data

Ronnie Gentry, MD

Internal Medicine · Houston, TXNPI 1740266303

Payments from drug & device makers

$1,200in general payments, 2019–2025

Across 58 payments — averaging $20.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$216
  • Gilead$185
  • Boston Scientific$141
  • Abbott$133
  • Lilly USA, LLC$122
  • AbbVie$102
  • plus $301 from 9 others

What the payments were for

  • Food & beverage$1,200100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,200 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$90,635
Medicare patients
320
Services billed
1,001

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin121$159,488
OzempicSemaglutide93$125,071
MounjaroTirzepatide96$124,040
XareltoRivaroxaban53$65,281
EliquisApixaban45$48,185
TrulicityDulaglutide31$32,890
JanuviaSitagliptin Phosphate13$22,281
MyrbetriqMirabegron17$13,412
Breo ElliptaFluticasone/Vilanterol11$7,487
Ezetimibe199$7,101
Rosuvastatin Calcium500$6,686
SynthroidLevothyroxine Sodium79$6,023
Losartan Potassium359$4,649
Atorvastatin Calcium343$3,846
Metoprolol Succinate191$3,657

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$122$156,929127 claims
Novo NordiskOzempic$21$125,07193 claims
Johnson & JohnsonXarelto$42$65,28153 claims
PfizerEliquis$216$48,18545 claims
Astellas Pharma US IncMyrbetriq$17$13,41217 claims
AbbVieSynthroid, Armour Thyroid$102$7,13291 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →